Mena Farag

@drmfarag.bsky.social

٣٤ ⋅ Doctor ⋅ MBBS, MRCP, PhD ⋅ Neurology SpR (ST7) https://orcid.org/0000-0002-0679-0117

The oncogenic KRAS mutation has been the subject of intense investigation. In The Lancet, a new phase 3 trial reports on adagrasib versus docetaxel in KRASG12C-mutated non-small-cell lung cancer. This and more in our latest issue 👉 bit.ly/4mi7T1y

Cover of The Lancet, August 9 2025 issue. Quote: "Adagrasib demonstrated statistically significant improvements in progression-free survival over docetaxel in patients with previously treated KRASG12C-mutated non-small cell lung cancer."

I am unbelievably proud to have my first senior author paper published today! It was a long slog through multiple review cycles but we got there! A big thank you to my lab members and all the collaborators and participants who contributed to this work! 🥲

House of Byrne Lab@hob-lab.bsky.social · last yr.

We are delighted to present the first publication out of the lab, available online today, titled ‘Evaluating finger-prick blood collection for remote quantification of neurofilament light in neurological diseases’ link.springer.com/article/10.1...